… says GlobalData
NLS Pharmaceutics has recently announced new data confirming that its narcolepsy product, a controlled release (CR) formulation of mazindol, has agonist activity at orexin-2 receptors (OX2R). While mazindol is a monoamine reuptake inhibitor like the many other stimulants used to treat narcolepsy, the additional OX2R agonist activity could give it a competitive edge in the market, says GlobalData, a leading data and analytics company. „Potential for novel narcolepsy treatment if it can overcome safety concerns“ weiterlesen